Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Дата публикации: 14-07-2026 20:07:35

CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)	0	9.64	22-06-2026
2	Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis	0	10.88	21-07-2026
3	BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1	0	20.6	22-07-2026
4	Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile	0	16.82	10-08-2026
5	BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1	0	19.89	12-05-2026
6	Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)	0	12.6	30-06-2026
7	BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9	0	19.68	27-05-2026
8	Ascelia Pharma Provides Update on the Orviglance NDA	0	11.3	03-07-2026
9	An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows	0	6.02	14-07-2026
10	Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety	0	10.31	25-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.04. Источник: www.drugs.com.